The DN Automotive case, in which workers were given lead-chelation injections to lower their blood lead levels ahead of special health examinations, has fueled calls to strengthen the health examination system. The company is suspected of undermining a system intended to protect workers' health by lowering test results instead of improving working conditions. Critics say the case exposed a legal gap, as the current Occupational Safety and Health Act contains no clear provision directly penalizing the act itself.


According to relevant government ministries, the Ministry of Employment and Labor's comprehensive audit on Oct. 27 is expected to focus on the legal basis for penalizing efforts to artificially lower health examination results and the scope of responsibility for employers and medical institutions.


The crux of the case is that systems for measuring working conditions and conducting special health examinations, both designed to protect workers' health, can be rendered ineffective by lowering test results. The current Occupational Safety and Health Act requires employers to measure working conditions and provide special health examinations, but does not explicitly prohibit administering chelation treatment before an examination to lower blood lead levels.


Another problem is that it is difficult to directly penalize the administration of chelation treatment under the Occupational Safety and Health Act alone. The Ministry of Employment and Labor considers the act to undermine the purpose of the system and has asked police to investigate. It is reviewing whether other laws, including those on obstruction of business and medical services, could apply. However, critics say there are limits to the investigation and efforts to establish responsibility because the injections were administered at a general medical institution, not one designated by the ministry to conduct special health examinations.

Minister of Employment and Labor Kim Younghoon delivers opening remarks during a parliamentary audit of the Ministry of Employment and Labor at the National Assembly on Oct. 13, 2026. Photo by Yoon Dongju.

Minister of Employment and Labor Kim Younghoon delivers opening remarks during a parliamentary audit of the Ministry of Employment and Labor at the National Assembly on Oct. 13, 2026. Photo by Yoon Dongju.

View original image

Rules on Prohibition and Retesting System Need Detail

The case has prompted calls for explicit standards and a legal basis for penalties to regulate efforts to artificially lower health examination results. The scope of regulation, critics say, should focus on conduct intended to conceal exposure to hazardous substances or distort test results, rather than on whether a specific drug was administered. "The Occupational Safety and Health Act currently does not allow us to penalize the problem of lowering blood lead levels in advance through chelation injections," said Ryu Hyuncheol, head of the Ministry of Employment and Labor's Occupational Safety and Health Headquarters. "If the National Assembly discusses legislation to penalize acts that undermine the occupational safety and health system, we will actively cooperate."


Clarifying the scope of responsibility for employers and medical institutions is also a key task. The aim is to establish standards for differentiating responsibility based on factors such as whether an employer ordered the injections or covered their cost, and whether the medical institution knew about the circumstances in advance. "As a general rule, chelation treatment should not be administered when lead poisoning has not been confirmed," said Myung Junpyo, a professor of occupational and environmental medicine at Seoul St. Mary's Hospital, Catholic University of Korea. To avoid discouraging medically necessary treatment, authorities should consider ways to distinguish injections given for legitimate medical purposes from those intended to lower test results.


Additional procedures to verify the reliability of health examination results are also under consideration. If an unusual change occurs, such as a sharp drop in blood lead levels just before an examination, authorities could review the patient's medication history alongside working-condition measurements and conduct further tests if necessary. The key will be to protect workers' medical information while ensuring the independence of testing institutions and establishing retesting procedures.


Some also point out that blood lead levels alone cannot determine whether working conditions are safe. The system should be strengthened so that test results are considered alongside actual exposure levels to hazardous substances and the risks of work processes, leading to follow-up measures such as improving working conditions or separating hazardous processes. "We plan to review the overall occupational health management system to ensure that measurements of working conditions and special health examinations actually protect workers' right to health," a Ministry of Employment and Labor official said.

U.S. Bans Preventive Chelation, with Treatment as an Exception

Other countries have responded by preventing conduct that undermines systems designed to protect workers' health or by tightening exposure limits for hazardous substances. Under its lead exposure standards, the U.S. Occupational Safety and Health Administration (OSHA) prohibits employers, as well as people they employ or supervise, from administering chelation treatment to workers for preventive purposes. The rule is intended to prevent drug treatment to lower blood lead levels from being used as a substitute for improving working conditions.


However, chelation treatment for lead poisoning or diagnostic purposes is not completely prohibited. The rules require treatment to be supervised by a licensed physician and accompanied by appropriate medical monitoring, and workers must be notified in writing before treatment. The framework distinguishes the purpose of the treatment and its medical necessity; the fact that it took place at a medical institution does not, by itself, make it legitimate treatment.



The European Union (EU) has tightened lead exposure limits separately from its regulation of chelation treatment itself. Under a directive revised in 2024, the workplace lead exposure limit was lowered from 0.15 mg per cubic meter of air to 0.03 mg. Other major countries, including Germany and Japan, also strictly control any artificial medical intervention that could distort the objectivity of biological monitoring.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing